Products
Eldelumab Biosimilar Monoclonal Antibody (CXCL10) for Research
Pre-Made Eldelumab biosimilar, Whole mAb, Anti-CXCL10 Antibody: Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-168-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Eldelumab biosimilar, Whole mAb, Anti-CXCL10 Antibody: Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 therapeutic antibody |
| INN Name | Eldelumab |
| Target | CXCL10 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Bristol-Myers Squibb;Medarex |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries |
| Development Tech | Medarex UltiMAb Mouse |
About target - CXCL10
1. Protein C-X-C motif chemokine 10
2. Gene CXCL10
3. Organism Homo sapiens (Human)
Function
Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects (PubMed:7540647, PubMed:11157474, PubMed:22652417).
Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity).
Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization (PubMed:12750173, PubMed:19151743).
In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation (PubMed:12750173, PubMed:12663757).
Activation of the CXCL10/CXCR3 axis plays also an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization (By similarity).
